PDCD1 and neoplasm: Numerous studies demonstrate that some patients treated with immunotherapy against PD-1/PD-L1 tend to have a favorable prognosis, such as tumor shrinkage, durable responses, and prolonged survival, in a wide range of malignancies, including head and neck cancer [1].